{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:00:05Z","timestamp":1790848805397,"version":"4.1.0"},"reference-count":98,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"DOI":"10.1001\/jama.2020.6019","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T11:33:10Z","timestamp":1586777590000},"source":"Crossref","is-referenced-by-count":1069,"title":["Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)"],"prefix":"10.1001","author":[{"given":"James M.","family":"Sanders","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas"},{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite L.","family":"Monogue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas"},{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz Z.","family":"Jodlowski","sequence":"additional","affiliation":[{"name":"Pharmacy Service, VA North Texas Health Care System, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Cutrell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"issue":"8","key":"jrv200005r1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019.","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"jrv200005r3","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.","author":"Hoffmann","journal-title":"Cell"},{"issue":"4","key":"jrv200005r4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.v92.4","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis.","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"key":"jrv200005r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7","article-title":"Coronaviruses: an overview of their replication and pathogenesis.","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol Biol"},{"key":"jrv200005r6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fmicb.2014.00296","article-title":"Coronavirus infection, ER stress, apoptosis and innate immunity.","volume":"5","author":"Fung","year":"2014","journal-title":"Front Microbiol"},{"issue":"11","key":"jrv200005r7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"jrv200005r8","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"jrv200005r9","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.","author":"Zhou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"jrv200005r10","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","author":"Devaux","journal-title":"Int J Antimicrob Agents"},{"key":"jrv200005r11","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.","author":"Colson","journal-title":"Int J Antimicrob Agents"},{"key":"jrv200005r15","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","author":"Yao","journal-title":"Clin Infect Dis"},{"key":"jrv200005r16","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","author":"Gautret","journal-title":"Int J Antimicrob Agents"},{"key":"jrv200005r17","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19).","author":"Chen","journal-title":"J Zhejiang Univ (Med Sci)"},{"issue":"4","key":"jrv200005r20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1128\/AAC.00339-08","article-title":"Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.","volume":"53","author":"Lim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"jrv200005r21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings.","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"8","key":"jrv200005r22","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"jrv200005r23","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19.","author":"Cao","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv200005r27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol.","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"jrv200005r28","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures [in Russian].","volume":"53","author":"Khamitov","year":"2008","journal-title":"Vopr Virusol"},{"key":"jrv200005r29","article-title":"Clinical Features of 69 cases with coronavirus disease 2019 in Wuhan, China.","author":"Wang","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jrv200005r30","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses.","volume":"60","author":"Siegel","year":"2017","journal-title":"J Med Chem"},{"key":"jrv200005r31","article-title":"Remdesivir as a possible therapeutic option for the COVID-19.","author":"Al-Tawfiq","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"jrv200005r32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"jrv200005r33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development.","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr Opin Infect Dis"},{"issue":"9","key":"jrv200005r37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects.","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"issue":"3","key":"jrv200005r38","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis.","volume":"28","author":"Morra","year":"2018","journal-title":"Rev Med Virol"},{"issue":"1","key":"jrv200005r39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"jrv200005r41","article-title":"Treating COVID-19\u2014off-label drug use, compassionate use, and randomized clinical trials during pandemics.","author":"Kalil","journal-title":"JAMA"},{"issue":"12","key":"jrv200005r43","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.3899\/jrheum.110686","article-title":"Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.","volume":"38","author":"Osadchy","year":"2011","journal-title":"J Rheumatol"},{"issue":"1","key":"jrv200005r44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19).","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov Ther"},{"key":"jrv200005r45","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.","author":"Yao","year":"2020","journal-title":"J Med Virol"},{"issue":"6","key":"jrv200005r46","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study.","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong Med J"},{"key":"jrv200005r47","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.","author":"Wu","journal-title":"JAMA Intern Med"},{"issue":"10","key":"jrv200005r48","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cid\/ciy760","article-title":"Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients.","volume":"68","author":"Foolad","year":"2019","journal-title":"Clin Infect Dis"},{"key":"jrv200005r49","article-title":"Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study.","author":"Arabi","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jrv200005r50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SGA.0000000000000404","article-title":"Hepatitis C virus infection in pregnancy: an update.","volume":"43","author":"Altinbas","year":"2020","journal-title":"Gastroenterol Nurs"},{"key":"jrv200005r51","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.","author":"Wang","journal-title":"JAMA"},{"issue":"4","key":"jrv200005r52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2019.1581171","article-title":"Broad-spectrum coronavirus antiviral drug discovery.","volume":"14","author":"Totura","year":"2019","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"jrv200005r53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","volume":"19","author":"Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"jrv200005r54","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion.","volume":"90","author":"Coleman","year":"2016","journal-title":"J Virol"},{"issue":"18","key":"jrv200005r55","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies.","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"issue":"10","key":"jrv200005r56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PLoS Pathog"},{"issue":"pt 11","key":"jrv200005r57","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","article-title":"Cyclosporin A inhibits the replication of diverse coronaviruses.","volume":"92","author":"de Wilde","year":"2011","journal-title":"J Gen Virol"},{"issue":"3","key":"jrv200005r58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"3","key":"jrv200005r59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.","volume":"9","author":"Rossignol","year":"2016","journal-title":"J Infect Public Health"},{"key":"jrv200005r60","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","author":"Gurwitz","journal-title":"Drug Dev Res"},{"issue":"10043","key":"jrv200005r64","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: a case report.","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"jrv200005r65","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States.","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv200005r67","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"2","key":"jrv200005r68","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease.","volume":"15","author":"Mentr\u00e9","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"jrv200005r69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"jrv200005r70","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"12","key":"jrv200005r71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006034","article-title":"QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.","volume":"11","author":"Chinello","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"jrv200005r72","doi-asserted-by":"publisher","first-page":"866","DOI":"10.5414\/CP202388","article-title":"Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults.","volume":"53","author":"Kumagai","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"jrv200005r74","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development of therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases.","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent Sci"},{"issue":"10223","key":"jrv200005r76","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"jrv200005r77","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome.","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv200005r78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13054-019-2395-8","article-title":"The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis.","volume":"23","author":"Ni","year":"2019","journal-title":"Crit Care"},{"issue":"10229","key":"jrv200005r79","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression.","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"10229","key":"jrv200005r80","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"jrv200005r82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19.","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"jrv200005r83","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.","volume":"10","author":"Soo","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"jrv200005r84","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.","volume":"4","author":"Arabi","year":"2015","journal-title":"Springerplus"},{"issue":"4","key":"jrv200005r85","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jrv200005r86","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"jrv200005r87","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma.","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"jrv200005r88","article-title":"High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019.","author":"Cao","journal-title":"Open Forum Infect Dis"},{"issue":"10223","key":"jrv200005r91","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"jrv200005r92","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"jrv200005r93","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.","author":"Yang","journal-title":"Lancet Respir Med"},{"key":"jrv200005r94","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore.","author":"Young","journal-title":"JAMA"},{"key":"jrv200005r95","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China.","author":"Guan","journal-title":"N Engl J Med"},{"key":"jrv200005r34","year":"2017"},{"key":"jrv200005r35"},{"key":"jrv200005r66","author":"Kujawski"},{"key":"jrv200005r73","author":"Chen"},{"key":"jrv200005r75"},{"key":"jrv200005r90"},{"key":"jrv200005r2","unstructured":"Chinese Clinical Trials. http:\/\/www\/chictr.org\/enindex.aspx. Accessed March 31, 2020."},{"key":"jrv200005r12","unstructured":"National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia. Accessed March 18, 2020. https:\/\/www.chinalawtranslate.com\/wp-content\/uploads\/2020\/03\/Who-translation.pdf"},{"key":"jrv200005r13","unstructured":"Chloroquine [database online]. Hudson, OH: Lexicomp Inc; 2016. Accessed March 17, 2020. http:\/\/online.lexi.com"},{"key":"jrv200005r14","unstructured":"Aralen (chloroquine phosphate) [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2008. Accessed March 17, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/006002s045lbl.pdf"},{"key":"jrv200005r18","unstructured":"Hydroxychloroquine [database online]. Hudson, OH: Lexicomp Inc; 2016. Accessed March 17, 2020. http:\/\/online.lexi.com"},{"key":"jrv200005r19","unstructured":"Plaquenil (Hydroxychloroquine sulfate) [package insert]. St Michael, Barbados: Concordia Pharmaceuticals Inc; 2018. Accessed March 17, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/009768Orig1s051lbl.pdf"},{"key":"jrv200005r24","unstructured":"Lopinavir\/ritonavir [database online]. Hudson (OH): Lexicomp Inc; 2016. Accessed March 17, 2020. http:\/\/online.lexi.com"},{"key":"jrv200005r25","unstructured":"Kaletra (Lopinavir and ritonavir) [package insert]. North Chicago, IL: Abbvie; 2019. Accessed March 17, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021226s048lbl.pdf"},{"key":"jrv200005r26","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed March 17, 2020. http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/ AdultandAdolescentGL.pdf"},{"key":"jrv200005r36","unstructured":"Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2019. Accessed March 17, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125276s127,125472s040lbl.pdf"},{"key":"jrv200005r40","unstructured":"ClinicalTrials.gov. Accessed March 18, 2020. https:\/\/clinicaltrials.gov\/"},{"key":"jrv200005r42","unstructured":"Interview with David Juurlink. Coronavirus (COVID-19) update: chloroquine\/hydroxychloroquine and azithromycin.? JAMA. March 24, 2020. Accessed April 3, 2020. https:\/\/edhub.ama-assn.org\/jn-learning\/audio-player\/18337225"},{"key":"jrv200005r61","unstructured":"American Heart Association. Patients taking angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blocker (ARB) medications should continue therapy as prescribed [news release]. Published March 17, 2020. Accessed March 18, 2020. https:\/\/newsroom.heart.org\/news\/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician"},{"key":"jrv200005r62","unstructured":"European Society for Cardiology. Position statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Published March 13, 2020. Accessed March 18, 2020. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang"},{"key":"jrv200005r63","unstructured":"World Health Organization. WHO R&D blueprint: ad-hoc expert consultation on clinical trials for Ebola therapeutics. Published October 2018. Accessed March 20, 2020. https:\/\/www.who.int\/ebola\/drc-2018\/summaries-of-evidence-experimental-therapeutics.pdf"},{"key":"jrv200005r81","unstructured":"Sanofi. Sanofi and Regeneron begin global Kevzara (sarilumab) clinical trial program in patients with severe COVID-19 [news release]. Published March 16, 2020. Accessed March 18, 2020. http:\/\/www.news.sanofi.us\/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19"},{"key":"jrv200005r89","unstructured":"US Food and Drug Administration. Investigational COVID-19 Convalescent plasma: emergency INDs. Updated April 3, 2020. Accessed March 26, 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/investigational-covid-19-convalescent-plasma-emergency-inds"},{"key":"jrv200005r96","unstructured":"Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) clinical care. Updated March 30, 2020. Accessed March 18, 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-guidance-management-patients.html"},{"key":"jrv200005r97","doi-asserted-by":"crossref","unstructured":"World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Updated March 13, 2020. Accessed March 18, 2020. https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected","DOI":"10.15557\/PiMR.2020.0003"},{"key":"jrv200005r98","doi-asserted-by":"crossref","unstructured":"Kupferschmidt? K, Cohen? J. WHO launches global megatrial of the four most promising coronavirus treatments. Science. Published March 22, 2020. Accessed March 23, 2020. https:\/\/www.sciencemag.org\/news\/2020\/03\/who-launches-global-megatrial-four-most-promising-coronavirus-treatments#","DOI":"10.1126\/science.abb8497"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2764727\/jama_sanders_2020_rv_200005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T11:16:58Z","timestamp":1615202218000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2764727"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":98,"URL":"https:\/\/doi.org\/10.1001\/jama.2020.6019","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737733437.793573644","asserted-by":"object"}]},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,13]]}}}